Aims: To investigate the clinicopathological characteristics of 20 primary gastric T-cell lymphoma (GTCL) cases without human T-lymphotropic virus type I infection in Japan, a non-endemic area for coeliac disease.
Methods And Results: Fifteen cases had no history of persistent diarrhoea or severe hypoproteinaemia. Histologically, 13 cases (65%) consisted of large cell lymphoma and seven (35%) were of medium-sized cells. Intraepithelial lymphoma cell invasion was found in three cases (15%). Two of 10 surgical cases (20%) showed intramucosal tumour cell spreading with enteropathy-like features. Helicobacter pylori CagA gene was detected in three of 10 cases (30%). The lymphoma cells of all 20 cases were positive for CD3 and/or TCRbetaF1 and negative for CD56. CD4- and CD8- lymphoma was found in 11 cases (55%), CD4+ lymphoma in seven (35%) and CD8+ lymphoma in two (10%). CD30+, CD5+ and CD25+ lymphomas were detected in nine (45%), 10 (50%) and 11 (55%) cases, respectively. Five-year survival of the 16 available cases was 54%. Early clinical stage and medium-sized cell lymphoma were significantly (P < 0.05) better prognostic factors.
Conclusions: Patients with GTCL exhibit distinct clinicopathological findings and prognoses from those with enteropathy-associated T-cell lymphomas. GTCL may be mainly derived from lamina propria and parafollicular T cells.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1111/j.1365-2559.2009.03430.x | DOI Listing |
QJM
January 2025
HRB Clinical Research Facility Galway, School of Medicine, University of Galway, Galway, Ireland.
Background: The optimal approach to the diagnosis of atrial fibrillation in primary care is unclear.
Aim: To determine if external loop recorder (ELR) screening improves atrial fibrillation detection in community dwelling adults with a CHA2DS2-VASc score of greater than two.
Design: Randomised cross-over clinical trial.
Allergol Immunopathol (Madr)
January 2025
Department of Genetics and Molecular Biology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran;
Common variable immunodeficiency (CVID) is the most common symptomatic and heterogeneous type of inborn errors of immunity (IEI). However, the pathogenesis process of this disease is often unknown. Epigenetic modifications may be involved in unresolved patients.
View Article and Find Full Text PDFAllergol Immunopathol (Madr)
January 2025
Department of Pediatrics, University Hospital of Ioannina, Ioannina, Greece.
Anaphylaxis, the most severe end of the spectrum of allergic reactions, has shown increasing incidence globally over recent years. This hypersensitivity reaction can occur at any age, including infancy. Recent data, although scarce, show that anaphylaxis is increasingly reported in infancy, with food identified as the leading cause of anaphylaxis cases in this age group.
View Article and Find Full Text PDFAllergol Immunopathol (Madr)
January 2025
Department of Pediatric Respiratory Medicine, Anhui Provincial Children's Hospital, Hefei City, Anhui Province, China.
This study aimed to investigate the factors influencing the complication of allergic rhinitis in children with bronchial asthma and to construct a nomogram model to predict the occurrence of allergic rhinitis. A total of 190 children with bronchial asthma admitted to our hospital from August 2020 to August 2024 were retrospectively analyzed. The children were randomly divided into the training cohort (133 cases) and validation cohort (57 cases) in a ratio of 7:3.
View Article and Find Full Text PDFAllergol Immunopathol (Madr)
January 2025
Department of Allergy and Clinical Immunology, Firooz Abadi Hospital, Iran University of Medical Sciences, Tehran, Iran;
Background: Hymenoptera venom allergy is a potentially severe allergic reaction in the general population. The only preventative approach in these cases is venom immunotherapy (VIT), which follows different protocols. The recommended initial dose is 0.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!